Form D · Other Health Care
Nucleus Radiopharma, Inc.
Palo Alto, CA · CIK 0002004065
Offering snapshot reported Apr 11, 2024 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 4, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 11, 2024 | Initial | $6,000,000 | No comparison | 3 | SEC filing |
| Apr 11, 2024 | Initial | $66,099,956 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-510388
Preferred Stock can convert to underlying shares of Common Stock.
Source: Form D, filed Apr 11, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Justin Butler | Director |
| Charles Conroy | Director, Executive |
| Chris Mc Donald | Director |
| Manu Nair | Director |
| Tyrell Rivers | Director |
| Michael Rossi | Director |
| Norman Sharpless | Director |
| Mary Kate Wold | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
514 High Street
Palo Alto, CA, 94301
Palo Alto, CA, 94301